SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
AVIR

Atea Pharmaceuticals, Inc. (AVIR)

NASDAQ: AVIR · Real-Time Price · USD
Healthcare · Biotechnology
$3.96-$0.16 (-3.88%)
 
Market cap
$318M
Insider Score
Analyst consensus
Market Cap$318.00M+36.4%
Revenue (ttm)n/a
Net Income-$155.40M
EPS-$1.95
Shares Out80.30M
PE Ration/a
Forward PE-2.91
Dividendn/a
Ex-Dividend Daten/a
Volume448,459
Open$4.11
Previous Close$4.12
Day's Range$3.85 - $4.18
52-Week Range$2.92 - $6.45
Beta0.72
AnalystsBuy
Price Target$9.00(+127.27%)
Earnings DateNov 9, 2026

About AVIR

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Address
225 Franklin Street, Boston, MA, 02110, United States
Market Cap
318 million
Employees
55
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$0
Bought
$25.45K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

1 Day
-4.19%
5 Days
-6.58%
1 Month
-4.63%
6 Months
-0.48%
1 Year
+36.42%

$AVIR stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in AVIR holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by AVIR's directors and management

Net Shares Purchased by Insiders−1−102025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

AVIR Estimated quarterly lobbying spending

Source: U.S. Senate LDA

AVIR Revenue by Segment

$3.91MTotal
Stock based compensation$3.47M88.74%
Consulting and professional fees$440.00K11.26%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New AVIR patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to AVIR from public contracts

Source: USAspending.gov

Bull Case vs Bear Case

AI-generated from AVIR’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
No data yet
—
Analyst Ratings
62% of score
85
News & Sentiment
38% of score
72

News check: Q3 earnings reported with $200M credit facility secured, indicating financial stability and operational progress.

Recent Insider Activity

Buys
1
Sells
0
Buy Value
$25.45K
Distinct Buyers
1

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

GERMETFMG Treatments, Testing and Advancements ETF0.66%
BUSMEA Series Trust - EA Bridgeway Ultra-Small Company Market ETF0.29%
OMFSInvesco Russell 2000 Dynamic Multifactor ETF0.20%
IWCiShares Micro-Cap ETF0.07%
IBBQInvesco Nasdaq Biotechnology ETF0.02%
IBBiShares Biotechnology ETF0.02%
BIBProShares Ultra Nasdaq Biotechnology0.01%
JHMHJohn Hancock Multifactor Health Care ETF0.01%
PKWInvesco BuyBack Achievers ETF0.01%
VHTVanguard Health Care ETF0.00%

Weight is the stock’s share of each fund’s holdings.